Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients

Bone

Volumn 22, Issue 5, 1998, Pages 577-582

  Herrala, J ^a   Puolijoki, H ^a   Liippo, K ^b   Raitio, M ^b   Impivaara, O ^c   Tala, E ^b   Nieminen, M M ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Asthma; Bisphosphonates; Clodronate; Corticosteroids; Osteoporosis

Indexed keywords

CLODRONIC ACID; CORTICOSTEROID;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHMA; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; GASTRITIS; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BONE DENSITY; CLODRONIC ACID; DENSITOMETRY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FEMUR; FEMUR NECK; GLUCOCORTICOIDS; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; PREDNISOLONE;

EID: 0031981521     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00051-9     Document Type: Article

References (39)

1. Adinoff, A. D. and Hollister, J. R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268; 1983.
2. Delmas, P., Chapuy, M. C., Vignon, E., Briancon, D., Charon, S., and Meunier, P. J. Traitement de l'hypercalcemie d'origine metastasique osseuse par le dichloromethylene diphosphonate [Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcemia produced from bone metastases]. Nouv Presse Med 11:1471-1474; 1982.
3. Dempster, D., Arlot, M., and Meunier, P. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410-417; 1983.
4. 2MDP) in Paget's disease of bone. Arthritis Rheum 23:1185-1192; 1980a.
5. Douglas, D. L., Russell, R. G. G., Preston, C. J. et al. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcemia due to primary hyperparathyroidism or malignant disease. Lancet 1:1043-1047; 1980.
6. Elomaa, I., Blomqvist, C., Porkka, L. et al. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism. Cancer Treat Rep 68:655-657; 1984.
7. Fleisch, H. Biphosphonates. Mechanisms of action and clinical application. In: Peck, W., Ed. Bone and Mineral Research. Annual 1. Amsterdam: Excerpta Medica; 1983; 319-357.
8. Fleisch, H. Diphosphonates and Osteoporosis. In: Barzel, U. S., Ed. New York: Grune and Stratton; 1979; 205-222.
9. Fogelman, I., Smith, L., Mazess, R., Wilson, M. A., and Bevan, J. A. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 24:57-62; 1986.
10. Gallacher, S. J., Fenner, J. A., Anderson, K., Bryden, F. M., Banham, S. W., Logue, F. C., Cowan, R. A., and Boyle, I. T. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: An open pilot study. Thorax 47:932-936; 1992.
11. Gennari, C. Clucocorticosteroids and bone. In: Peck, W. A., Ed. Bone and Mineral Research/3. Amsterdam: Elsevier; 213-232; 1985.
12. Harris, S. T., Neer, R. M., Segre, G. V. et al. Secondary hyperparathyroidism associated with dichloromethylene diphosphonate treatment of Paget's disease. J Clin Endocrinol Metab 55:1100-1107; 1982.
13. Herrala, J., Puolijoki, H., Impivaara, O., Liippo, K., Tala, E., and Nieminen, M. M. Bone mineral density in asthmatic women on high-dose inhaled bechlomethasone dipropionate. Bone 15:621-623; 1994.
14. Jacobs, T. P., Siris, E. S., Balezikian, J. P., Baguiran, D. C., Shane, E., and Canfield, R. E. Hypercalcemia of malignancy: Treatment with intravenous dichloromethylene disphosphonate. Ann Intern Med 94:312-316; 1981.
15. Khosla, S., Lufkin, E. G., Fitzpatrick, L. A., and Melton, L. J., III. Epidemiology and clinical features of osteoporosis in young individuals. Bone 15:551-555; 1994.
16. Kröger, H., Heikkinen, J., Laitinen, K., and Kotaniemi, A. Dual energy X-ray absorptiometry in normal women: A cross-sectional study of 717 Finnish volunteers. Osteoporos Int 2:135-140; 1992.
17. Laitinen, K., Välimaki, M., and Keto, P. Bone mineral density measured by dual-energy X-ray absorptiometry in healthy Finnish women. Calcif Tissue Int 48:224-231; 1991.
18. Lipworth, B. J. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 50:105-110; 1995.
19. LoCascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., and DellaRocca, C. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39-51; 1990.
20. Lukert, B. P. Etidronate in the management of glucocorticoid-induced osteoporosis. Am J Med 99:233-234; 1995.
21. Lukert, B. and Raisz, L. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 112:352-364; 1990.
22. Meunier, P., Birancon, D., Dhavassieux, P. et al. Treatment with fluoride: Bone histomorphometric findings. In: Christianssen, C., Johanssen, J. S., and Riis, B. J., Eds. Osteoporosis. Copenhagen: Osteopress; 824-828; 1987.
23. Mulder, H. and Struys, A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348-350; 1994.
24. Pentikäinen, P. J., Elomaa, I., Nurmi, A. K., and Kärkkainen, S. Pharmacocinetics of clodronate in patients with metastatic breast cancer. Lancet 39:218; 1986.
25. Plosker, G. L. and Goa, K. L. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47:945-982; 1994.
26. Powell, J. H. and Demark, B. R. Clinical pharmacokinetics of diphosphonates. In: Garattini, S., Ed. Bone Resorption Metastasis and Diphosphonates. New York: Raven; 41-49; 1985.
27. Rastad, J., Benson, L., Johansson, H. et al. Clodronate treatment in patients with malignancy associated hypercalcemia. Acta Med Scand 221:489-494; 1987.
28. Recker, R. R. and Saville, P. D. Interstinal absorption of disodium ethane-1-,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol 24:580; 1973.
29. Reid, I. R., Heap, S. W., King, A. R., and Ibbertson, H. K. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet ii:1144-1145; 1988.
30. Reid, I. R., King, A. R., Alexander, C. J., and Ibbertson, H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet i:143-146; 1988.
31. Ruegsegger, P., Medici, T. C., and Anliker, M. Corticosteroid-induced bone loss. A longitudinal study of alternative day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 25: 615-620; 1983.
32. Sebalt, R. J., Adachi, J. D., Bensen, W. G., Bianchi, F., Cividano, A., Graig, G. L., Granney, A., Kaminska, E., Gordon, M., Steele, M., and Goldsmith, C. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: A two years of follow-up. Scan J Rheumatol 103(Suppl.):91-93; 1996.
33. Sewell, K. Modern therapeutic approaches to osteoporosis. Rheum Dis Clin North Am 15:583-614; 1983.
34. Sievänen, H., Oja, P., and Vuori, I. Precision of dual-energy X-ray absorptiometry in determining bone mineral density and content of various skeletal sites. J Nucl Med 33:1137-1142; 1992.
35. Struys, A., Snelder, A. A., Snelder, R. N., and Mulder, H. Cyclical etidronate reverses bone loss of the spine and proximal femus in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235-242; 1995.
36. Walsh, L. J., Wong, C. A., Pringle, M., and Tattersfield, A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. Br Med J 313:344-346; 1996.
37. WHO Study Group, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis 3. Assessment of bone mass. WHO Technical Report Series 843. Geneva World Health Organization; 25-50; 1994.
38. Wink, C., Onge, M., and Parker, B. The effects of dichloromethylene bisphosphonate on osteoporotic femora of adult castrate male rats. Acta Anat 124: 117-121; 1985.
39. Yakatan, G. J., Poyner, W. J., Talberg, R. L., Floyd, B. F., Slough, C. L., Ampulski, R. F., and Benedict, J. J. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 31:402-410; 1982.